EQUTY INVESTMENT (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended |
|---|---|---|---|
Dec. 18, 2018 |
Jun. 30, 2020 |
Jun. 30, 2020 |
|
| Equity Method Goodwill | $ 5,000,000 | $ 5,000,000 | |
| ILiAD [Member] | |||
| Advisory and legal expenses | $ 41,000 | ||
| ILiAD [Member] | Tranche One [Member] | |||
| Initial investment | $ 2,500,000 | ||
| Description for the terms of allowed-to-proceed notice under aggrement | Which was followed by additional investments of $1,000,000 and $1,500,000 in May and August 2019, respectively, which were triggered by ILiAD’s receipt of an “allowed to proceed” notice from the FDA permitting ILiAD to advance to the phase 2b clinical study of its BPZE1 vaccine. In connection with its investment, the Company’s Chairman and Chief Executive Officer obtained a seat on ILiAD’s Board of Managers and receives the same compensation for service on the Board of Managers as other non-management Board members. | ||
| ILiAD [Member] | Tranche Two [Member] | |||
| Initial investment | $ 2,500,000 | ||
| Class C units [Member] | ILiAD [Member] | |||
| Ownership percentage fully diluted | 8.30% | 8.30% | |
| Share of net loss of equity investment | $ (205,000) | $ (498,000) | |
| Ownership percentage - non fully diluted | 9.50% | 9.50% | |
| Maximum [Member] | ILiAD [Member] | |||
| Company total investment | 5,000,000 | ||
| Maximum [Member] | Class C units [Member] | |||
| Total offering | $ 16,200,000 |